Adma Biologics reports Q2 EPS 14c, consensus 14c

Reports Q2 revenue $121,98M, consensus $121.77M. The company said, “”The second quarter was another highly productive period for ADMA, highlighted by strong year-over-year underlying revenue and earnings growth, adjusting for a prior-year non-recurring item. We are confidently reaffirming all previously issued financial guidance, with growth rates anticipated to accelerate significantly in the second half of 2025 and beyond. Importantly, we commenced commercial-scale manufacturing with our FDA-approved yield enhancement process, and initial production batches are delivering the anticipated 20%+ increase in finished IG output. The successful initiation of yield-enhanced manufacturing marks a key inflection point-driving expected gross margin expansion, reinforcing ADMA’s forecasted growth trajectory, and positioning the Company for an accelerating pace of revenue and earnings growth in the periods ahead.”